Mlinarič-Raščan I - Search Results

1

Prevalence and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in Kosovo.

Pasha F, Urbančič D, Maxhuni R, Krasniqi S, Grajçevci Uka V, Mlinarič-Raščan I. Pasha F, et al. Among authors: mlinaric rascan i. Cancers (Basel). 2024 May 23;16(11):1988. doi: 10.3390/cancers16111988. Cancers (Basel). 2024. PMID: 38893109 Free PMC article.

2

A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering.

Murn J, Mlinaric-Rascan I, Vaigot P, Alibert O, Frouin V, Gidrol X. Murn J, et al. BMC Genomics. 2009 Jul 17;10:323. doi: 10.1186/1471-2164-10-323. BMC Genomics. 2009. PMID: 19607732 Free PMC article.

3

Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.

Gobec M, Prijatelj M, Delić J, Markovič T, Mlinarič-Raščan I. Gobec M, et al. Eur J Pharmacol. 2014 Nov 5;742:81-8. doi: 10.1016/j.ejphar.2014.08.039. Epub 2014 Sep 9. Eur J Pharmacol. 2014. PMID: 25218986

4

Characterization of human lymphoblastoid cell lines as a novel in vitro test system to predict the immunotoxicity of xenobiotics.

Markovič T, Gobec M, Gurwitz D, Mlinarič-Raščan I. Markovič T, et al. Toxicol Lett. 2015 Feb 17;233(1):8-15. doi: 10.1016/j.toxlet.2014.12.013. Epub 2014 Dec 24. Toxicol Lett. 2015. PMID: 25542143

5

99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.

Gmeiner Stopar T, Fettich J, Zver S, Mlinaric-Rascan I, Hojker S, Socan A, Peitl PK, Mather S. Gmeiner Stopar T, et al. Nucl Med Commun. 2008 Dec;29(12):1059-65. doi: 10.1097/MNM.0b013e3283134d6e. Nucl Med Commun. 2008. PMID: 18987526 Clinical Trial.

6

Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients.

Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Karas-Kuzelicki N, et al. Leukemia. 2009 May;23(5):971-4. doi: 10.1038/leu.2008.317. Epub 2008 Nov 6. Leukemia. 2009. PMID: 18987660 No abstract available.

7

Medicines associated with folate-homocysteine-methionine pathway disruption.

Vidmar M, Grželj J, Mlinarič-Raščan I, Geršak K, Dolenc MS. Vidmar M, et al. Arch Toxicol. 2019 Feb;93(2):227-251. doi: 10.1007/s00204-018-2364-z. Epub 2018 Nov 29. Arch Toxicol. 2019. PMID: 30499019 Review.

8

B cell receptor signaling involves physical and functional association of FAK with Lyn and IgM.

Mlinaric-Rascan I, Yamamoto T. Mlinaric-Rascan I, et al. FEBS Lett. 2001 Jun 1;498(1):26-31. doi: 10.1016/s0014-5793(01)02474-7. FEBS Lett. 2001. PMID: 11389892 Free article.

9

(99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.

Stopar TG, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ. Stopar TG, et al. Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):53-9. doi: 10.1007/s00259-005-1838-4. Epub 2005 Sep 20. Eur J Nucl Med Mol Imaging. 2006. PMID: 16172899

10

Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.

Švajger U, Gobec M, Obreza A, Mlinarič-Raščan I. Švajger U, et al. Cancer Immunol Immunother. 2015 Jan;64(1):15-27. doi: 10.1007/s00262-014-1608-x. Epub 2014 Sep 25. Cancer Immunol Immunother. 2015. PMID: 25253531 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters